Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Terminated 4Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Head and Neck Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Neoplasms, Squamous Cell 2

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × zalutumumab × Clear all
NCT00542308 2023-08-03

Zalutumumab in Non-curable Patients With SCCHN

Genmab

Phase 2 Completed
90 enrolled 10 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT01054625 2023-08-03

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Genmab

Phase 1/2 Completed
31 enrolled 16 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00093041 2023-06-28

Zalutumumab in Head and Neck Cancer

Genmab

Phase 1/2 Completed
28 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00382031 2013-10-15

Zalutumumab in Patients With Non-curable Head and Neck Cancer

Genmab

Phase 3 Completed
286 enrolled 12 charts
Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡